ABUS Arbutus Biopharma Corporation

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 9, 2014 

---

Tekmira Pharmaceuticals Corporation
(Exact name of registrant as specified in its charter)

British Columbia, Canada	001-34949	980597776
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

100-8900 Glenlyon Parkway Burnaby, British Columbia Canada	V5J 5J8
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code:   (604) 419-3200

________________________________________________________________________________
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	[   ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	[   ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	[   ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	[   ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

Item 8.01. Other Events.

On October 9, 2014 the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

    Exhibit 99.1.       Press release dated October 9, 2014

---

SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Tekmira Pharmaceuticals Corporation (Registrant)
October 9, 2014 (Date)		/s/   BRUCE G. COUSINS Bruce G. Cousins Executive Vice President and Chief Financial Officer

---

	Exhibit Index
	99.1	Press release dated October 9, 2014

EXHIBIT 99.1

Tekmira to Present HBV Pre-Clinical Data at Meeting of the Oligonucleotide Therapeutics Society

VANCOUVER, British Columbia, Oct. 9, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that Dr. Ian MacLachlan, Tekmira's Executive Vice President and Chief Technical Officer, will present preclinical data for TKM-HBV, the Company's product candidate targeting hepatitis B virus, at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society. The presentation will take place on Wednesday, October 15, 2014 at 12 pm (PT) / 3 pm (ET) in San Diego at The Hilton San Diego Resort and Spa.

Presentation Information

On October 15, the Company will be issuing a press release highlighting key components of the presentation. The presentation will also be available after the podium event on Tekmira's website in the events section at www.tekmira.com.

About Tekmira

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle (LNP) delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering LNPs. Further information about Tekmira can be found at www.tekmira.com. Tekmira is based in Vancouver, B.C. Canada.

CONTACT: Investors Julie P. Rezler Director, Investor Relations Phone: 604-419-3200 Email: jrezler@tekmira.com Media Please direct all media inquiries to media@tekmira.com